Table 2.
Odds Ratios (ORs) and 95% confidence intervals (CIs) describing the association between patient HIV status and stage of disease at diagnosis
| Cancer Site | Total Cases (N%) | HIV-infected cases (N,%) | HIV-uninfected cases (N,%) | Model 1, not adjusted for healthcare factors a | Model 2, adjusted for healthcare factors b |
|---|---|---|---|---|---|
| Oral Cavity/Pharynx/Larynx | |||||
| Stage I | 65128 (22.5) | 127 (13.5) | 65001 (22.5) | 1 | 1 |
| Stage II | 38100 (13.2) | 108 (11.5) | 37992 (13.2) | 1.32(1.02,1.71) | 1.24(0.96,1.6) |
| Stage III | 50123 (17.3) | 176 (18.7) | 49947 (17.3) | 1.52(1.21,1.91) | 1.38(1.1,1.74) |
| Stage IV | 136292 (47.1) | 528 (56.2) | 135764 (47.0) | 1.54(1.27,1.88) | 1.35(1.1,1.64) |
| P-trend | 0.0001 c | 0.0134 | |||
| Stomach | |||||
| Stage I | 28157 (26.5) | 76 (26.2) | 28081 (26.5) | 1 | 1 |
| Stage II | 15341 (14.5) | 43 (14.8) | 15298 (14.5) | 1.01(0.69,1.47) | 1.03(0.71,1.5) |
| Stage III | 15783 (14.9) | 39 (13.4) | 15744 (14.9) | 0.83(0.56,1.23) | 0.85(0.58,1.26) |
| Stage IV | 46779 (44.1) | 132 (45.5) | 46647 (44.1) | 0.95(0.71,1.26) | 0.94(0.71,1.26) |
| P-trend | 0.7826 | 0.7070 | |||
| Colorectum | |||||
| Stage I | 181014 (23.1) | 465 (22.9) | 180549 (23.1) | 1 | 1 |
| Stage II | 208371 (26.6) | 616 (30.3) | 207755 (26.6) | 1.16(1.03,1.31) | 1.13(1,1.27) |
| Stage III | 227004 (29.0) | 557 (27.4) | 226447 (29.0) | 1(0.88,1.13) | 0.98(0.87,1.11) |
| Stage IV | 167612 (21.4) | 396 (19.5) | 167216 (21.4) | 0.94(0.82,1.08) | 0.89(0.78,1.02) |
| P-trend | 0.1559 | 0.0313 | |||
| Anus | |||||
| Stage I | 6130 (19.9) | 229 (21.8) | 5901 (19.8) | 1 | 1 |
| Stage II | 11996 (39.0) | 385 (36.6) | 11611 (39.0) | 0.86(0.72,1.02) | 0.83(0.7,0.99) |
| Stage III | 10064 (32.7) | 369 (35.1) | 9695 (32.6) | 0.9(0.76,1.08) | 0.86(0.72,1.03) |
| Stage IV | 2603 (8.5) | 69 (6.6) | 2534 (8.5) | 0.57(0.43,0.76) | 0.54(0.41,0.73) |
| P-trend | 0.0100 | 0.0027 | |||
| Liver | |||||
| Stage I | 38333 (35.6) | 242 (29.4) | 38091 (35.7) | 1 | 1 |
| Stage II | 21727 (20.2) | 165 (20.0) | 21562 (20.2) | 1.1(0.9,1.35) | 1.09(0.89,1.33) |
| Stage III | 27884 (25.9) | 246 (29.9) | 27638 (25.9) | 1.27(1.06,1.52) | 1.31(1.09,1.57) |
| Stage IV | 19600 (18.2) | 170 (20.7) | 19430 (18.2) | 1.19(0.97,1.45) | 1.24(1.02,1.52) |
| P-trend | 0.0309 | 0.0084 | |||
| Pancreas | |||||
| Stage I | 17995 (8.5) | 46 (9.2) | 17949 (8.5) | 1 | 1 |
| Stage II | 62661 (29.7) | 142 (28.5) | 62519 (29.7) | 0.84(0.6,1.17) | 0.84(0.6,1.17) |
| Stage III | 22989 (10.9) | 45 (9.0) | 22944 (10.9) | 0.65(0.43,0.99) | 0.65(0.43,0.98) |
| Stage IV | 107574 (50.9) | 265 (53.2) | 107309 (50.9) | 0.83(0.6,1.13) | 0.82(0.6,1.13) |
| P-trend | 0.5813 | 0.5703 | |||
| Lung | |||||
| Stage I | 238623 (21.1) | 790 (18.8) | 237833 (21.1) | 1 | 1 |
| Stage II | 63768 (5.6) | 224 (5.3) | 63544 (5.6) | 0.91(0.79,1.06) | 0.92(0.79,1.07) |
| Stage III | 293173 (25.9) | 1090 (25.9) | 292083 (25.9) | 0.94(0.85,1.03) | 0.93(0.84,1.01) |
| Stage IV | 534742 (47.3) | 2097 (49.9) | 532645 (47.3) | 0.97(0.89,1.05) | 0.97(0.89,1.05) |
| P-trend | 0.8945 | 0.9718 | |||
| Melanoma | |||||
| Stage I | 172448 (65.5) | 110 (51.4) | 172338 (65.5) | 1 | 1 |
| Stage II | 42586 (16.2) | 35 (16.4) | 42551 (16.2) | 1.12(0.77,1.65) | 1.05(0.71,1.54) |
| Stage III | 32356 (12.3) | 38 (17.8) | 32318 (12.3) | 1.52(1.05,2.21) | 1.41(0.97,2.06) |
| Stage IV | 15737 (6.0) | 31 (14.5) | 15706 (6.0) | 2.37(1.58,3.56) | 1.96(1.3,2.97) |
| P-trend | <0.0001 | 0.0022 | |||
| Female breast | |||||
| Stage I | 692293 (47.7) | 453 (37.8) | 691840 (47.8) | 1 | 1 |
| Stage II | 502964 (34.7) | 419 (35) | 502545 (34.7) | 1.2(1.05,1.37) | 1.16(1.02,1.33) |
| Stage III | 179480 (12.4) | 185 (15.5) | 179295 (12.4) | 1.36(1.14,1.62) | 1.26(1.06,1.5) |
| Stage IV | 75217 (5.2) | 140 (11.7) | 75077 (5.2) | 2.36(1.95,2.85) | 2.06(1.70,2.50) |
| P-trend | <0.0001 | <0.0001 | |||
| Cervix | |||||
| Stage I | 45105 (47.4) | 146 (44.2) | 44959 (47.4) | 1 | 1 |
| Stage II | 14506 (15.2) | 53 (16.1) | 14453 (15.2) | 1.2(0.87,1.65) | 1.05(0.76,1.45) |
| Stage III | 22528 (23.7) | 78 (23.6) | 22450 (23.7) | 1.05(0.79,1.38) | 0.92(0.69,1.22) |
| Stage IV | 13083 (13.7) | 53 (16.1) | 13030 (13.7) | 1.42(1.03,1.96) | 1.22(0.88,1.69) |
| P-trend | 0.0866 | 0.5754 | |||
| Prostate | |||||
| Stage I/II d | 939405 (82.7) | 1190 (78.7) | 938215 (82.7) | 1 | 1 |
| Stage III | 115700 (10.2) | 135 (8.9) | 115565 (10.2) | 0.97(0.82,1.17) | 0.96(0.8,1.15) |
| Stage IV | 81192 (7.1) | 188 (12.4) | 81004 (7.1) | 1.81(1.55,2.12) | 1.57(1.34,1.83) |
| P-trend | <0.0001 | <0.0001 | |||
| Bladder | |||||
| Stage I | 81514 (46.2) | 170 (43.1) | 81344 (46.2) | 1 | 1 |
| Stage II | 46726 (26.5) | 118 (29.9) | 46608 (26.5) | 1.2(0.95,1.52) | 1.19(0.94,1.5) |
| Stage III | 18135 (10.3) | 36 (9.1) | 18099 (10.3) | 0.9(0.63,1.29) | 0.89(0.62,1.28) |
| Stage IV | 29945 (17.0) | 70 (17.8) | 29875 (17.0) | 1.04(0.78,1.38) | 1(0.75,1.33) |
| P-trend | 0.7419 | 0.8901 | |||
| Kidney | |||||
| Stage I | 185725 (59.0) | 412 (58.2) | 185313 (59.0) | 1 | 1 |
| Stage II | 28666 (9.1) | 56 (7.9) | 28610 (9.1) | 0.81(0.61,1.08) | 0.84(0.64,1.11) |
| Stage III | 46784 (14.9) | 105 (14.8) | 46679 (14.9) | 1.05(0.85,1.31) | 1.07(0.86,1.33) |
| Stage IV | 53635 (17.0) | 135 (19.1) | 53500 (17.0) | 1.09(0.89,1.32) | 1.06(0.87,1.3) |
| P-trend | 0.6677 | 0.6752 | |||
| Thyroid | |||||
| Stage I | 207173 (72.1) | 149 (57.3) | 207024 (72.1) | 1 | 1 |
| Stage II | 23217 (8.1) | 23 (8.8) | 23194 (8.1) | 0.94(0.59,1.48) | 0.92(0.58,1.45) |
| Stage III | 35457 (12.3) | 42 (16.2) | 35415 (12.3) | 1.23(0.85,1.78) | 1.15(0.8,1.67) |
| Stage IV | 21436 (7.5) | 46 (17.7) | 21390 (7.5) | 1.95(1.36,2.81) | 1.67(1.16,2.41) |
| P-trend | 0.0007 | 0.0072 |
a
Model 1 adjustment: age, sex, race, calendar year of cancer diagnosis, median household income (by zip code)
b
Model 2 adjustment: age, sex, race, calendar year of cancer diagnosis, median household income (by zip code), patient-reported individual health insurance, type of treating cancer facility
c
Bolded text denotes statistical significant for the P-trend test describing the likelihood of diagnosis with more advanced stages of disease by HIV status
d
Individual stage groupings with less than 10 patients collapsed into categories to provide more stable effect estimates (e.g., stage I and stage II prostate cancer patients combined into stage I/II disease)